Ligand id: 10168

Name: ravulizumab

Compound class Antibody
Approved drug? Yes (FDA (2018), EMA (2019))
International Nonproprietary Names
INN number INN
10659 ravulizumab
ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds to human complement component C5. It was developed by Alexion as a next-generation anti-C5 therapy for paroxysmal nocturnal hemoglobinuria (PNH) that was engineered from their already approved PNH agent eculizumab, but was designed to have an inhherently longer circulating half-life so as to extend dosing intervals to once/month [3].
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
Database Links
Specialist databases
IMGT/mAb-DB 674
Other databases
GtoPdb PubChem SID 381118878
Search PubMed clinical trials ravulizumab
Search PubMed titles ravulizumab
Search PubMed titles/abstracts ravulizumab